NEOGENOMICS INC — Director's Dealing 2022

Apr 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2022-04-01

Reporting Person: Sholehvar David (President, Clinical Services)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-04-01	Common Stock	A	30864	—	Acquired	30864	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-01	Stock Option (Right to Buy)	$12.15	A	66372	Acquired	2029-04-01	Common Stock (66372.0)	Direct

Footnotes

F1: On April 1, 2022, Dr. Sholehvar was granted 30,864 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date.

F2: On April 1, 2022, Dr. Sholehvar was granted 66,372 stock options. These options vest ratably over the first four anniversary dates of the grant date.